Product Description: Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Mark H O'Hara, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021 Jan;22(1)
CAS Number: 2305607-45-6
Molecular Weight: N/A
Compound Purity: 98.90
Research Area: Cancer; Inflammation/Immunology
Solubility: H2O
Target: Others